Aliskiren vs. Angiotensin Receptor Blockers in Hypertension: Meta-Analysis of Randomized Controlled Trials | Zendy

D. Gao | Zendy; Ning Ning | Zendy; Xiaolin Niu | Zendy; Jia Wei | Zendy; Peipei Sun | Zendy; Guang Hao | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Aliskiren vs. Angiotensin Receptor Blockers in Hypertension: Meta-Analysis of Randomized Controlled Trials

Author(s) -

D. Gao,

Ning Ning,

Xiaolin Niu,

Jia Wei,

Peipei Sun,

Guang Hao

Publication year - 2011

Publication title -

american journal of hypertension

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.009

H-Index - 136

eISSN - 1941-7225

pISSN - 0895-7061

DOI - 10.1038/ajh.2011.3

Subject(s) - medicine , aliskiren , angiotensin receptor blockers , irbesartan , pharmacology , randomized controlled trial , cardiology , renin–angiotensin system , blood pressure

Aliskiren, a newly discovered renin inhibitor, blocks the renin-angiotensin system (RAS) from the top of the enzyme cascade and therefore, might provide comparable or even superior clinical efficacy of blood pressure (BP) control than angiotensin receptor blockers (ARBs). With this meta-analysis, we aimed to compare the efficacy and tolerability of aliskiren and ARBs in the treatment of hypertension in the short-term treatment period.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research